Brain fog as a neurological manifestation of post-COVID-19 syndrome in a female patient with rheumatoid arthritis

Authors

Keywords:

COVID-19, mental fatigue, post-acute COVID-19 syndrome, rheumatoid arthritis, rheumatic disease.

Abstract

Introduction: Neurological manifestations can be expressed as part of the complications of rheumatoid arthritis and COVID-19. In patients with both conditions the inflammatory process can affect other organs and organ systems.
Objective: To present a female patient, with a diagnosis of rheumatoid arthritis and a history of COVID-19 in whom the diagnosis of brain fog was made.
Clinical Case: Female patient, 52 years old, with a diagnosis of rheumatoid arthritis of 9 years of evolution and a history of COVID-19 4 months ago, which began with neurological manifestations consisting of disorders of memory, concentration, attention and frequent headache. Laboratory tests showed the presence of an inflammatory process; no alterations were found in the imaging studies. The diagnosis of brain fog syndrome was confirmed. The therapeutic scheme was maintained and psychological care was added. There was improvement in the clinical picture and follow-up is maintained with both specialties.
Conclusions: The complexity of rheumatoid arthritis affecting joints and other organ systems is illustrated; COVID-19 also affects the neurological system, presenting brain fog as an expression of post-COVID-19 syndrome.

Downloads

Author Biographies

Urbano Solis Cartas, Universidad Nacional de Chimborazo Escuela Superior politécnica de Chimborazo Hospital Andino de Chimborazo

Especialista en Reumatología

Pedro Renato Flores Brito, Escuela Superior Politécnica de Chimborazo

Médico General

Alex Daniel Barreno Gadvay, Universidad Nacional de Chimborazo

Psicólogo clínico

Omarys Chang Calderin, Universidad Nacional de Chimborazo

Especialista en Medicina General

References

1. Greenblatt HK, Kim HA, Bettner LF, Deane KD. Artritis reumatoide preclínica y prevención de la artritis reumatoide [Internet]. Opinión actual en reumatología. 2020 [acceso: 17/04/2024]; 32(3):289-96. Disponible en: https://journals.lww.com/co-rheumatology/abstract/2020/05000/preclinical_rheumatoid_arthritis_and_rheumatoid.12.-aspx?context=latestarticles

2. Solis Cartas U, Valdés González JL. Autoanticuerpos y sistema de histocompatibilidad en pacientes con diagnóstico de artritis reumatoide [Internet]. Rev Cub Med Milit. 2022 [acceso: 11/04/2024]; 51(3):e02202059. Disponible en: http://scielo.sld.cu/scielo.php?pid=S0138-65572022000300014&script=sci_arttext&tlng=en

3. Villafuerte Morales JE, Hernández Batista SDLC, Chimbolema Mullo SO, Pilamunga Lema CL. Manifestaciones cardiovasculares en pacientes con enfermedades reumáticas y COVID-19 [Internet]. Revista Cubana de Reumatología. 2021 [acceso: 14/04/2024]; 23(1):e190. Disponible en: https://revreumatologia.sld.cu/index.php/reumatologia/article/view/870/pdf

4. Cairol E, Monteghirfo R, Yandián M, Torres V, Guillermo C, Bruno G, et al. Sindrome pos-covid-19: pautas de Diagnóstico y Tratamiento. Uruguay: Sociedad de Medicina Interna del Uruguay [Internet]; 2021. [acceso: 13/04/2024]. Disponible en: https://www.medicinainterna.org.uy/wpcontent/uploads/2021/08/SIND-POST-COVID19-SMIU.pd

5. Carod-Artal FJ. Síndrome post COVID-19: epidemiología, criterios diagnósticos y mecanismos patogénicos implicados [Internet]. Rev neurol. 2021 [acceso: 08/04/2024]; 72(2):384-96. Disponible en: https://www.neurologia.com/articulo/2021230

6. Theoharides C, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue [Internet]. Biofactors. 2021 [acceso: 15/04/2024]; 47(2):232-41. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250989/

7. Fernández SD, Zaldivar YP, Duran LRL, Ramos DMT, García MR. La" niebla mental", una manifestación neurocognitiva del síndrome post-COVID-19 [Internet]. Rev Cub Med Milit. 2023 [acceso: 12/04/2024]; 52(4):02302463. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article/view/2463#:~:text=Conclusiones-%3A%20Los%20s%C3%ADntomas%20neurocognitivos%20de,pacientes%20que%2-0presentaron%20enfermedad%20grave

8. Solis-Cartas U, Valdés-González J, Chang-Calderin O, Tinajero-Novillo L. Relación existente entre COVID-19 y enfermedades reumáticas a partir de sus semejanzas etiopatogénicas [Internet]. Revista Cubana de Reumatología. 2024 [acceso: 12/04/2024]; 26:e1215. Disponible en: https://revreumatologia.sld.cu/index.php/reumatologia/article/view/1215

9. Mariscal Chacón JA. Consecuencias neurocognitivas, niebla mental post covid 19 en el municipio de Zacapa [Internet]. Revista Académica Sociedad del Conocimiento Cunzac. 2023 [acceso: 15/04/2024]; 3(2):17-24. Disponible en: https://revistasociedadcunzac.com/index.php/revista/article/view/86

10. Quintana-Castro P, Garcia-Melendez DD, Morales-Casado MI. Alteraciones en el olfato tras 6 meses de la infección por SARS-CoV-2 [Internet]. Medicina Clínica. 2022 [acceso: 14/04/2024]; 159(1):54. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136587/

Downloads

Published

2024-08-03

How to Cite

1.
Solis Cartas U, Flores Brito PR, Barreno Gadvay AD, Chang Calderin O. Brain fog as a neurological manifestation of post-COVID-19 syndrome in a female patient with rheumatoid arthritis. Rev Cubana Med Milit [Internet]. 2024 Aug. 3 [cited 2025 Apr. 7];53(3):e024059982. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/59982

Issue

Vol. 53 No. 3 (2024): July - September

Section

Case Presentation

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.